I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Fukuhara, Tatsuro
79
results:
Search for persons
X
Format
Online (79)
Mediatypes
Articles (Online) (51)
OpenAccess-fulltext (28)
Languages
english (77)
Sorted by: Relevance
Sorted by: Year
?
1
First-line nivolumab plus ipilimumab with or without chemot..:
Imai, Hisao
;
Kijima, Takashi
;
Azuma, Koichi
...
Japanese Journal of Clinical Oncology. 54 (2024) 4 - p. 452-462 , 2024
Link:
https://doi.org/10.1093/..
?
2
Monitoring of Plasma EGFR Mutations during Osimertinib Trea..:
Watanabe, Kana
;
Saito, Ryota
;
Miyauchi, Eisaku
...
Cancers. 15 (2023) 17 - p. 4231 , 2023
Link:
https://doi.org/10.3390/..
?
3
First-line nivolumab plus ipilimumab in metastatic non-smal..:
Nishio, Makoto
;
Ohe, Yuichiro
;
Ikeda, Satoshi
...
International Journal of Clinical Oncology. 28 (2023) 10 - p. 1354-1368 , 2023
Link:
https://doi.org/10.1007/..
?
4
Detection of multiple druggable mutations of lung cancer fr..:
Fujita, Kazutaka
;
Arai, Ryo
;
Shoji, Satoshi
...
Cancer Science. 114 (2023) 8 - p. 3342-3351 , 2023
Link:
https://doi.org/10.1111/..
?
5
Health Care Resource Use Among Patients with Advanced Non–S..:
Goto, Yasushi
;
Kawamura, Kodai
;
Fukuhara, Tatsuro
...
Current Therapeutic Research. 99 (2023) - p. 100712 , 2023
Link:
https://doi.org/10.1016/..
?
6
Correction to: First-line nivolumab plus ipilimumab in meta..:
Nishio, Makoto
;
Ohe, Yuichiro
;
Ikeda, Satoshi
...
International Journal of Clinical Oncology. 28 (2023) 10 - p. 1369-1370 , 2023
Link:
https://doi.org/10.1007/..
?
7
Niacin restriction with NAMPT-inhibition is synthetic letha..:
Nomura, Miyuki
;
Ohuchi, Mai
;
Sakamoto, Yoshimi
...
Nature Communications. 14 (2023) 1 - p. , 2023
Link:
https://doi.org/10.1038/..
?
8
A Prospective Cohort Study Assessing the Relationship betwe..:
Fukuhara, Tatsuro
;
Imai, Kazuhiro
;
Nakagawa, Taku
...
Biomedicines. 11 (2023) 9 - p. 2501 , 2023
Link:
https://doi.org/10.3390/..
?
9
Pembrolizumab plus chemotherapy in Japanese patients with m..:
Sugawara, Shunichi
;
Tanaka, Kentaro
;
Imamura, Fumio
...
Cancer Science. 114 (2023) 8 - p. 3330-3341 , 2023
Link:
https://doi.org/10.1111/..
?
10
Phase II study of carboplatin–paclitaxel alone or with beva..:
Oizumi, Satoshi
;
Takamura, Kei
;
Harada, Toshiyuki
...
International Journal of Clinical Oncology. 27 (2022) 4 - p. 676-683 , 2022
Link:
https://doi.org/10.1007/..
?
11
Treatment with immune checkpoint inhibitors after EGFR‐TKIs..:
Ito, Takashi
;
Nagashima, Hiromi
;
Akiyama, Masachika
...
Thoracic Cancer. 13 (2021) 3 - p. 386-393 , 2021
Link:
https://doi.org/10.1111/..
?
12
First‐line pembrolizumab vs chemotherapy in metastatic non‐..:
Satouchi, Miyako
;
Nosaki, Kaname
;
Takahashi, Toshiaki
...
Cancer Science. 112 (2021) 12 - p. 5000-5010 , 2021
Link:
https://doi.org/10.1111/..
?
13
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐ce..:
Izumi, Hiroki
;
Matsumoto, Shingo
;
Liu, Jie
...
Nature. 600 (2021) 7888 - p. 319-323 , 2021
Link:
https://doi.org/10.1038/..
?
14
MK‐6, a novel not‐α IL‐2, elicits a potent antitumor activi..:
Kobayashi, Maki
;
Kojima, Katsuhiko
;
Murayama, Kazutaka
...
Cancer Science. 112 (2021) 11 - p. 4478-4489 , 2021
Link:
https://doi.org/10.1111/..
?
15
Randomized phase 2 study comparing irinotecan versus amrubi..:
Tanaka, Hisashi
;
Hasegawa, Yukihiro
;
Fujita, Yuka
...
Thoracic Cancer. 12 (2021) 14 - p. 2113-2121 , 2021
Link:
https://doi.org/10.1111/..
1-15